SUL-151
Diabetic Kidney Disease, COPD, Heart Failure, Neurodegeneration
Key Facts
About Sulfateq
Sulfateq is an innovative Dutch biotech leveraging insights from natural mitochondrial stress responses, such as hibernation, to develop novel small molecule therapies. Its lead programs target major chronic diseases including Parkinson's, diabetic kidney disease, COPD, and heart failure, with its most advanced asset, SUL-238, having a Phase II trial initiated by a partner. The company operates with a lean, experienced leadership team and a partnership-driven model to advance its pipeline of orally bioavailable compounds. Sulfateq's technology platform utilizes phenotypic screening to identify compounds that enhance mitochondrial function, addressing a significant unmet medical need in diseases of aging and metabolism.
View full company profile